136 related articles for article (PubMed ID: 31467231)
21. BRAFV600E Immunohistochemistry in Papillary Thyroid Carcinomas: Relationship Between Clinical and Morphological Parameters.
Kombak FE; Özkan N; Uğurlu MÜ; Kaya H
Turk Patoloji Derg; 2019; 35(2):83-91. PubMed ID: 30632125
[TBL] [Abstract][Full Text] [Related]
22. Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis with ARMS PCR.
Zhang J; Yang Y; Zhao J; Shi L; Xu Y; Yu K; Guo C
Pathol Res Pract; 2019 Apr; 215(4):761-765. PubMed ID: 30819583
[TBL] [Abstract][Full Text] [Related]
23. Increased Expression of GARP in Papillary Thyroid Carcinoma.
Zhang X; Guo M; Yang J; Zheng Y; Xiao Y; Liu W; Ren F
Endocr Pathol; 2019 Mar; 30(1):1-7. PubMed ID: 30443770
[TBL] [Abstract][Full Text] [Related]
24. Rosettes in papillary carcinoma of thyroid: A rare cytomorphological indicator of aggressive variants.
Nambirajan A; Batool S; Mandal P; Nakra T; Agarwal S; Jain D
Cytopathology; 2017 Dec; 28(6):560-562. PubMed ID: 29165889
[No Abstract] [Full Text] [Related]
25. Prognostic significance of extranodal extension of regional lymph node metastasis in papillary thyroid cancer.
Wu MH; Shen WT; Gosnell J; Duh QY
Head Neck; 2015 Sep; 37(9):1336-43. PubMed ID: 24821456
[TBL] [Abstract][Full Text] [Related]
26. Role of Lin28A/let-7a/c-Myc Pathway in Growth and Malignant Behavior of Papillary Thyroid Carcinoma.
Huang J; Lin H; Zhong M; Huang J; Sun S; Lin L; Chen Y
Med Sci Monit; 2018 Dec; 24():8899-8909. PubMed ID: 30531691
[TBL] [Abstract][Full Text] [Related]
27. Expression of metastasis-associated genes h-mts1 (S100A4) and nm23 in carcinoma of breast is related to disease progression.
Albertazzi E; Cajone F; Leone BE; Naguib RN; Lakshmi MS; Sherbet GV
DNA Cell Biol; 1998 Apr; 17(4):335-42. PubMed ID: 9570150
[TBL] [Abstract][Full Text] [Related]
28. Autocrine activation of platelet-derived growth factor receptor α in metastatic papillary thyroid cancer.
Adewuyi EE; Deschenes J; Lopez-Campistrous A; Kattar MM; Ghosh S; McMullen TPW
Hum Pathol; 2018 May; 75():146-153. PubMed ID: 29408504
[TBL] [Abstract][Full Text] [Related]
29. Occult lymph node metastasis and risk of regional recurrence in papillary thyroid cancer after bilateral prophylactic central neck dissection: A multi-institutional study.
Lee YC; Na SY; Park GC; Han JH; Kim SW; Eun YG
Surgery; 2017 Feb; 161(2):465-471. PubMed ID: 27574773
[TBL] [Abstract][Full Text] [Related]
30. S100A4 (Mts1) gene overexpression is associated with invasion and metastasis of papillary thyroid carcinoma.
Zou M; Al-Baradie RS; Al-Hindi H; Farid NR; Shi Y
Br J Cancer; 2005 Nov; 93(11):1277-84. PubMed ID: 16265347
[TBL] [Abstract][Full Text] [Related]
31. [Risk factors analyses for lateral neck lymph node metastasis in papillary thyroid carcinoma].
Qi ZJ; Liu LF; Cheng L; Han X; Wang T; Li F; Lu C; Zhang AB
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Jul; 33(7):603-606. PubMed ID: 31327195
[No Abstract] [Full Text] [Related]
32. Identifying gene modules of thyroid cancer associated with pathological stage by weighted gene co-expression network analysis.
Tang X; Huang X; Wang D; Yan R; Lu F; Cheng C; Li Y; Xu J
Gene; 2019 Jul; 704():142-148. PubMed ID: 30965127
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological characteristics of thyroid cancer in the federal state of Salzburg.
Rendl G; Rodrigues M; Schweighofer-Zwink G; Hutter J; Hittmair A; Zellinger B; Hauser-Kronberger C; Pirich C
Wien Klin Wochenschr; 2017 Aug; 129(15-16):540-544. PubMed ID: 28493027
[TBL] [Abstract][Full Text] [Related]
34. Impact of BRAF V600E and TERT Promoter Mutations on Response to Therapy in Papillary Thyroid Cancer.
Trybek T; Walczyk A; Gąsior-Perczak D; Pałyga I; Mikina E; Kowalik A; Hińcza K; Kopczyński J; Chrapek M; Góźdź S; Kowalska A
Endocrinology; 2019 Oct; 160(10):2328-2338. PubMed ID: 31305897
[TBL] [Abstract][Full Text] [Related]
35. Lymph node ratio predicts recurrence in pediatric papillary thyroid cancer.
Rubinstein JC; Dinauer C; Herrick-Reynolds K; Morotti R; Callender GG; Christison-Lagay ER
J Pediatr Surg; 2019 Jan; 54(1):129-132. PubMed ID: 30361076
[TBL] [Abstract][Full Text] [Related]
36. [Clinical and biological features of familial nonmedullary thyroid carcinoma].
Gao J; Yu Y; Li X; Zhao J; Zhao C; Zhao J; Liu Y; Li Y; Gao M
Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):202-6. PubMed ID: 24785281
[TBL] [Abstract][Full Text] [Related]
37. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China.
Huang M; Yan C; Xiao J; Wang T; Ling R
Diagn Pathol; 2019 Jul; 14(1):74. PubMed ID: 31300059
[TBL] [Abstract][Full Text] [Related]
38. Secular trends in the prognostic factors for papillary thyroid cancer.
Choi H; Lim JA; Ahn HY; Cho SW; Lee KE; Kim KW; Yi KH; Sung MW; Youn YK; Chung JK; Park YJ; Park DJ; Cho BY
Eur J Endocrinol; 2014 Nov; 171(5):667-75. PubMed ID: 25163726
[TBL] [Abstract][Full Text] [Related]
39. Patients with Oncocytic Variant Papillary Thyroid Carcinoma Have a Similar Prognosis to Matched Classical Papillary Thyroid Carcinoma Controls.
Carr AA; Yen TWF; Ortiz DI; Hunt BC; Fareau G; Massey BL; Campbell BH; Doffek KL; Evans DB; Wang TS
Thyroid; 2018 Nov; 28(11):1462-1467. PubMed ID: 30215297
[TBL] [Abstract][Full Text] [Related]
40. AGK-BRAF is associated with distant metastasis and younger age in pediatric papillary thyroid carcinoma.
Sisdelli L; Cordioli MICV; Vaisman F; Moraes L; Colozza-Gama GA; Alves PAG; Araújo ML; Alves MTS; Monte O; Longui CA; Cury AN; Carvalheira G; Cerutti JM
Pediatr Blood Cancer; 2019 Jul; 66(7):e27707. PubMed ID: 30924609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
